HIGHLIGHTS
- who: Ricky M. Trigg from the Department University of Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge , QQ, UK have published the research work: The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS
- what: The authors proactively investigated mechanisms of resistance to ALK inhibitors using CRISPRa screens in NB cell lines harboring recurrent point mutations in the ALK tyrosine kinase domain, including those previously shown to confer endogenous resistance to the ALK inhibitor crizotinib.
- how: To further . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.